The “U.S. Biosimilars Market 2021” will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.
Leading Players operating in the U.S. Biosimilars Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Hoffmann-La Roche Ltd.,
- AbbVie Inc.,
- Merck & Co.,
- Celltrion Inc.,
- Coherus BioSciences, Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Eli Lilly and Company
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990
The report covers:
- Global U.S. Biosimilars Market trends, with detailed analysis on consumer trends & manufacturer trends.
- Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
- Key areas of investments identifying market opportunities and challenges in forecast timeframe.
- Competitive analysis of the industry players along with the overview on strategic management.
- Comprehensive company profiles of the major industry players.
Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position
Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis. Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM. It is a biosimilar to Neupogen that is approved to treat neutropenia. The FDA also granted approval for Truxima, the first biosimilar of rituximab in November 2018. It is developed by Celltrion Inc., a biopharmaceutical company headquartered in South Korea, for the treatment of non-Hodgkin’s lymphoma.
Increased Research and Development Initiatives to Drive the Market
Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-biosimilars-market-100990
Detailed Table of Content:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1 Prevalence of Key Disease Associated with the Scope – U.S., 2018
4.2 New Product Launch
4.3 Pipeline Analysis
4.4 Regulatory Scenario
4.5. Reimbursement Scenario
4.6. Patent Snapshot of Biologics
4.6 Key Industry Developments – Partnerships, Mergers & Acquisitions
- U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1 Filgrastim & Pegfilgrastim
5.2.2 Monoclonal Antibodies
5.2.2 Others
5.3. Market Analysis, Insights and Forecast – By Disease Indication
5.3.1 Cancer
5.3.2 Autoimmune Diseases
5.3.2.1 Arthritis
5.3.2.2 Psoriasis
5.3.2.3 Neutropenia
5.3.2.4 Others
5.3.3 Others
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1 Hospital Pharmacy
5.4.2 Retail Pharmacy
5.4.3 Online Pharmacy
- Competitive Analysis
6.1. Key Industry Developments
6.2. U.S. Market Share Analysis (2018)
6.3. Competition Dashboard
6.4. Comparative Analysis – Major Players
6.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
6.5.1 Novartis AG
6.5.2 Pfizer Inc.
6.5.3 Coherus BioSciences, Inc.
6.5.4 Teva Pharmaceutical Industries Ltd.
6.5.5 Merck & Co., Inc.
6.5.6 AbbVie Inc.
6.5.7 F. Hoffmann-La Roche Ltd.
6.5.8 Eli Lilly and Company
6.5.9 Celltrion Inc.
6.5.10 Amgen Inc.
6.5.11 Other Prominent Players
- Strategic Recommendations
Continued…
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990
Report Focus:
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential U.S. Biosimilars Market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
Reasons to Purchase this Report:
- Comprehensive analysis of the U.S. Biosimilars Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245